Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens

Prostate cancers, initially responsive to anti-androgen therapies, often advance to a hormone-refractory “castrate resistant” stage (CRPC). However the androgen receptor (AR) pathway remains active and key for cell growth and gene expression within tumours, even in the apparent absence of hormone. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Dart, D. A., Brooke, G. N., Sita-Lumsden, A., Waxman, J., Bevan, C. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3427022/
https://www.ncbi.nlm.nih.gov/pubmed/22179832
http://dx.doi.org/10.1038/onc.2011.591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3427022/
https://www.ncbi.nlm.nih.gov/pubmed/22179832
http://dx.doi.org/10.1038/onc.2011.591

Ejemplares similares